Sistema renina-angiotensina, deterioro cognitivo y demencia
Implicancias terapéuticas de su inhibición
farmacología
farmacología cardiovascular 22 | Agostode2013demostraron que los pacientes hipertensos que recibían BB tenían menos lesiones de tipo Alzheimer (placas de Ab y ovillos neurofibrilares) y menos lesiones vasculares de la sustancia blanca que aquellos que no recibieron tratamiento, o en quienes recibían otra clase de drogas (24). Aunque sin clara explicación, su efecto inhibidor sobre la renina podría estar actuando de consuno a la disminución de la Ang-II. Conclusiones De manera que la modulación del SRA pareciera cobrar relevancia no solo en la prevención de la patología cardio y cerebrovascular sino que su inhibición aportaría beneficios sobre el componente cognitivo de los pacientes hipertensos. En especial, los ARAs parecieran tener una indicación por sobre los IECA. Más allá de mejorar la función endotelial y la inflamación, los efectos mediados a través del receptor AT2 sobre el metabolismo del Ab y las vías colinérgicas, parecieran aportar un beneficio extra. No obstante, serán necesarios más estudios a gran escala, estandarizando incluso los métodos de evaluación cognitiva. Bibliografía recomendada 1. Snowdon DA, Greiner LH, Mortimer JA et al. Brain infarction and clinical expression of Alzheimer Disease. The Nun study. JAMA 1997;277:813-7. 2. Duron E, Hanon O. Vascular Risk factors, cognitive decline, and dementia. Vasc Health and Risk Management 2008;4:363-81. 3. INDEC. Instituto Nacional de Estadísticas y Censo. Disponible en: http://www.censo2010. indec.gov.ar/ Estimaciones y Proyecciones de la Población. Total del País 1950-2015. Consultado en febrero, 2013. 4. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomized doubleblind placebo-controlled Systolic Hypertension in Europe (Syst-Eur). Lancet 1998;352;1347-51. 5. Forette F, Seux ML, Staessen JA et al. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from Systolic Hypertension in Europe (Syst-Eur) study. Arch Int Med 2002;162:2046-52 6. Tzourio C, Anderson C, Chapman N et al. PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamida therapy on dementia and cognitive decline in patients with Cerebrovascular disease. Arch Int Med 2003;163:1069-75. 7. Bosch J, Yusuf S, Pogue J et al. HOPE Investigators. Heart Outcome prevention evaluation. Use of ramipril in preventing stroke: double blind randomized trial. BMJ 2002;324:699-702. 8. SHEP Cooperative Research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP) JAMA 1991;265:3255-64. 9. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86. 10. Diener HC, Sacco R, Yusuf S. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurology 2008;7:875-884. 11. Beckett PR, Forette F, Tuomilehto J et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2011;7:683-9. 12. Culamn J, Blume A, Gohlke P and Unger T. The rennin-angiotensin system in the brain: possible therapectic implications for AT1 receptor blockers. J Hum Hypertension 2002;16:S64-S70. 13. Kehoe PG and Wilcock GK. Is inhibition of rennin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet neurology 2007;6:373-78. 14. Muldoon MF, Waldstein SR Ryan CM et al. Effects of six antihypertensive medications on cognitive performance. J Hypertens 2002;20:1643-1652. 15. Tzourio C. Vascular factors and cognition: toward a prevention of dementia? J Hypertens 2003;21(suppl.5):S15-S19. 16. Fogari R. Preti P, Mugellini A et al. Influence of Losartan and atenolol on cognitive function in very elderly hypertensive patients. Am J Hypertens 2002;15:A36. 17. Li NC, Lee A, Whitmer RA and Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.BMJ 2010;340:b5465. 18. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. J Alzheimers Dis. 2011;26:699-708. 19. Hajjar I. Effects of anti-hypertensive Therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Int Med 2012:172:442-443. 20. Hajjar I, Brown N, Mark WJ, Chui H. Impact of angiotensin receptors blockers on Alzheimer’s disease neuropathology in a large brain autopsy series. Arch Neurol. Published online September 10, 2012. doi:10.1001/archneurol. 2012. 1010. 21. Vicario A, Martinez CD, Barreto D. Detección del daño cerebral en pacientes con hipertensión mediante una evaluación cognitiva mínima. Rev Fed Arg Cardiol 2006;35 (supl-1):S47. 22. Khachaturian AS, Zandi PP, Lyketsos CG, Breitner KA, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 2006;63:686-92. 23. Launer LJ, Ross GW, Petrovich H et al. Midlife blood pressure and dementia: Honolulu- Asian Aging Study (HAAS). Neurobiol Aging 2000;21:49-55. 24. Beta Blocker Treatment of Hypertensive Older Persons Ameliorates the Brain Lesions of Dementia Measured at Autopsy: the Honolulu- Asia Aging Study American Academy of Neurology's 65th Annual Meeting. Abstract 2171. http://www.aan.com/globals/axon/assets/ 10428.pdf Editorial Sciens | 17
